Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | GALR3 | O60755 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL779893 | 0.80 | MAPT (0.43) | MAPTFAAHTSHRCHRM2CHRM4 | |
| SCHEMBL2980611 | 0.80 | MAPT (0.43) | MAPTFAAHTSHRCHRM2CHRM4 | |
| SCHEMBL1216964 | 0.80 | MAPT (0.43) | MAPTFAAHTSHRCHRM2CHRM4 | |
| SCHEMBL6741818 | 0.79 | MAPT (0.40) | MAPTFAAHTSHRCHRM2CHRM4 | |
| SCHEMBL4439936 | 0.78 | MAPT (0.42) | MAPTFAAHTSHRCHRM2CHRM4 | |
| SCHEMBL7223633 | 0.78 | MAPT (0.42) | MAPTFAAHTSHRCHRM2CHRM4 | |
| SCHEMBL702238 | 0.78 | MAPT (0.42) | MAPTFAAHTSHRCHRM2CHRM4 | |
| Magnesium SCHEMBL29456102 | 0.78 | MAPT (0.42) | MAPTFAAHTSHRCHRM2CHRM4 | |
| SCHEMBL2978632 | 0.78 | MAPT (0.42) | MAPTFAAHTSHRCHRM2CHRM4 | |
| SCHEMBL28889016 | 0.78 | MAPT (0.42) | MAPTFAAHTSHRCHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2105432-A1 | Process for Producing Chromone Compound | Sumitomo Chemical Company, Limited (JP) | 2009-09-30 | — | — | EP | disclosed |
| EP-2105431-A1 | Process for Producing Chromone Compound | Sumitomo Chemical Company, Limited (JP) | 2009-09-30 | — | — | EP | disclosed |
| EP-1867626-A2 | Process for producing chromone compound | Sumitomo Chemical Company, Limited (JP) | 2007-12-19 | — | — | EP | disclosed |
| US-20060217565-A1 | Process for producing chromone compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-09-28 | — | — | US | disclosed |
| US-7094914-B2 | Process for producing chromone compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-08-22 | — | — | US | disclosed |
| US-20050085664-A1 | Process for producing chromone compound | SUMITOMO CHEMICAL COMPANY, LMITED (JP) | 2005-04-21 | — | — | US | disclosed |
| EP-1479667-A1 | PROCESS FOR PRODUCING CHROMONE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085664-A1 | Process for producing chromone compound | ENY2, CDY1; CDY1B, CDYL | MAPT 4765/4885FAAH 2814/4885TSHR 1710/4885 |
| US-20060217565-A1 | Process for producing chromone compound | ENY2, CDY1; CDY1B, CDYL | MAPT 4765/4885FAAH 2814/4885TSHR 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.